Japan first in the world to approve Dupixent for chronic spontaneous urticaria (CSU)
The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic spontaneous…
Read More...
Read More...
